MODERNA INC.
Commented by Fabian Lorenz on October 12th, 2026 | 05:30 CEST
After 600% Gains with Moderna! Cardiol Therapeutics Poised for a Revaluation - Analysts See Significant Upside Potential
With gains of more than 600%, Moderna is the Nasdaq’s best-performing stock so far this year. Much of its future growth potential may already be priced in, prompting Citigroup to recommend selling shares in the mRNA specialist. Analysts, however, see significant upside potential in another biotech company: Cardiol Therapeutics. The Canadian biotechnology company focuses on inflammatory heart diseases, and its lead drug candidate, CardiolRx™, is already in Phase 3 clinical trials. Following strong Phase 2 data, the stock more than doubled between July and September. After a subsequent pullback, could this present an attractive entry opportunity? In a recent interview, the CEO explains why he remains optimistic. Two research firms recommend buying the stock and see the potential for a multiple-fold increase in its share price.
Read
Commented by Fabian Lorenz on October 7th, 2026 | 08:35 CEST
Time to Sell Moderna Stock After a 200% Rally? A Comeback for Standard Lithium and HPQ Silicon?
Moderna's stock has had a spectacular run in recent weeks. Since mid-August, the biotech company's stock has surged from USD 63 to over USD 200. But now analysts are pouring cold water on the price surge. In their view, the stock could more than halve in value. While Moderna has already made a successful comeback, there are good reasons to believe that HPQ Silicon's is still to come. Despite positive news flow, the stock has yet to take off. Following successes in the drone sector, the company recently laid the groundwork to market its technology for producing fumed silica. Investors have been waiting for a comeback from Standard Lithium for quite some time. The stock is trading at a yearly low and approaching penny stock levels. Yet the company recently secured a new customer.
Read
Commented by Nico Popp on September 25th, 2026 | 07:50 CEST
Breakthroughs in Skin Cancer Treatment: New Approaches from Biofrontera and Moderna – Vidac Pharma Faces a Busy Fall
For a long time, the treatment of skin cancer and its precancerous stages resembled a makeshift compromise: Doctors used scalpels, froze affected areas, or prescribed aggressive creams that destroyed tissue. It was not uncommon for patients to suffer pain and weeks of delayed wound healing. But a completely new dynamic is currently emerging in the sector. Suddenly, innovations involving light beams, messenger RNA (mRNA), and the metabolic reprogramming of cancer cells are making headlines. We present the latest developments in skin cancer and its precancerous stages. The race for innovation has only just begun.
Read
Commented by Matthias Schomber on August 24th, 2026 | 08:20 CEST
Cancer Breakthrough and Defense Boom: BioNTech and Moderna Take Off! Can Volatus Aerospace Follow Suit?
In the capital markets, two entirely different future-oriented industries are simultaneously stepping into the spotlight. While in the biotech sector, hopes for groundbreaking cancer therapies are fueling a massive comeback for companies such as Moderna and BioNTech, a highly exciting turnaround candidate may be emerging in the specialized field of unmanned aviation. Investors are rightly asking themselves whether the recent optimism surrounding biotech stocks is underpinned by fundamental strength or whether it is merely a short-lived flash in the pan followed by a sell-off. Those who can now read the right signals in financial data and chart patterns may be able to identify which stocks are poised for the next major trend movements. We take a closer look for you.
Read
Commented by Stefan Feulner on August 24th, 2026 | 07:50 CEST
Merck, Vidac Pharma, Moderna: New Cancer Treatments Send Stock Markets Soaring
A breakthrough in cancer research sent the stock market into a frenzy last week. For the first time, a personalized mRNA therapy has achieved key endpoints in a large Phase 3 trial, adding billions in market value within hours. At the same time, smaller biotech companies are working on entirely different approaches to target tumors at one of their greatest vulnerabilities. The race for the next generation of cancer treatments is thus gaining momentum. The economic potential is enormous.
Read
Commented by Stefan Bode on August 21st, 2026 | 07:30 CEST
Three Stocks, Three Themes: Rally, Crash, and Comeback Potential—Lahontan Gold, Moderna and PFISTERER
Record profits, yet double-digit share price losses. On the stock market, it is not just earnings that count—it is the outlook for the future. That is precisely where some of the most interesting opportunities can emerge. We highlight a cyclical infrastructure stock with slowing momentum, a biotech company following a major medical breakthrough, and a commodities player benefiting from higher gold prices and project progress. Investors looking to determine whether these moves reflect market overreaction or genuine new developments will find the decisive signals in the numbers and outlooks.
Read
Commented by Tarik Dede on August 11th, 2026 | 07:20 CEST
Pharma and Biotech Stocks in the Spotlight: Moderna, BioNxt Solutions, and Eli Lilly
Many patents held by the major pharmaceutical giants are set to expire in the coming years. Once that protection is gone, companies face the risk of lost revenue due to copycat drugs, known as generics. Consequently, the stakes are currently very high in the industry. Acquisitions and massive investments in the research pipeline are shaping the landscape. The markets for oncology and weight-loss injections are particularly lucrative. The former is a matter of life and death, while the latter is mostly about appearance and health. At the same time, many countries need to reduce their healthcare costs. Demographic trends and many lifestyle-related diseases are taking their toll on people and health insurance premiums. For investors, this tension presents a wealth of opportunities. We are therefore taking a look today at the stocks of Moderna, BioNxt Solutions, and Eli Lilly.
Read
Commented by André Will-Laudien on July 15th, 2026 | 11:00 CEST
Sharp Swings in the Life Sciences Sector: Bayer, Vidac Pharma, BioNTech, Moderna, and Evotec in the Spotlight
Things are really heating up here! Cancer research is currently undergoing a historic turning point thanks to the convergence of cell analysis and digital precision. With a new management team, BioNTech is attempting to transition its revolutionary mRNA platform from COVID-19 to personalized cancer vaccines, while Bayer is strategically focusing on next-generation targeted radionuclide therapies. In the agricultural sector, the first signs of relief are finally emerging, as glyphosate is now being negotiated at the supranational level and has been classified as non-harmful by US authorities. At the same time, drug discovery company Evotec is grappling with a new revenue warning—and this one is particularly severe. Vidac Pharma is also coming into focus as a highly specialized innovator by blocking cancer metabolism to decisively manipulate the tumour microenvironment. These four distinct approaches impressively demonstrate that the victory over cancer no longer lies solely in traditional chemotherapies, but rather in highly specialized biotech companies and data-driven alliances. With so much news on the table, volatility is sure to follow.
Read
Commented by Nico Popp on October 16th, 2025 | 07:00 CEST
Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech
Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.
Read
Commented by Nico Popp on June 26th, 2025 | 07:05 CEST
Decoding the Code of Life – What comes next? Illumina, PanGenomic Health, Moderna
Genetic information is the blueprint of life. Even today, genome sequencing enables us to gain insights that can extend our lives. This is especially true when we can identify certain predispositions to diseases in advance and respond with a healthy lifestyle. Numerous business models are currently emerging around this technology. Some of these are very capital-intensive. Others leverage existing research and artificial intelligence, making them incredibly smart opportunities for investors.
We provide an overview.